| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial.
|
AIDS
|
2002
|
2.03
|
|
2
|
Identification of a highly divergent HIV type 2 and proposal for a change in HIV type 2 classification.
|
AIDS Res Hum Retroviruses
|
2004
|
1.73
|
|
3
|
Systemic non-Hodgkin lymphoma in HIV-infected patients with effective suppression of HIV replication: persistent occurrence but improved survival.
|
J Acquir Immune Defic Syndr
|
2002
|
1.63
|
|
4
|
Clinical atovaquone-proguanil resistance of Plasmodium falciparum associated with cytochrome b codon 268 mutations.
|
Microbes Infect
|
2006
|
1.56
|
|
5
|
Differences in proviral DNA load between HIV-1- and HIV-2-infected patients.
|
AIDS
|
2008
|
1.48
|
|
6
|
Imported malaria in HIV-infected patients enrolled in the ANRS CO4 FHDH study.
|
J Acquir Immune Defic Syndr
|
2008
|
1.46
|
|
7
|
Absence of efficacy of nonviable Lactobacillus acidophilus for the prevention of traveler's diarrhea: a randomized, double-blind, controlled study.
|
Clin Infect Dis
|
2006
|
1.42
|
|
8
|
French experience of 2009 A/H1N1v influenza in pregnant women.
|
PLoS One
|
2010
|
1.35
|
|
9
|
Plasma RNA viral load in human immunodeficiency virus type 2 subtype A and subtype B infections.
|
J Clin Microbiol
|
2002
|
1.32
|
|
10
|
In vitro phenotypic susceptibility of human immunodeficiency virus type 2 clinical isolates to protease inhibitors.
|
Antimicrob Agents Chemother
|
2008
|
1.30
|
|
11
|
High frequency of selection of K65R and Q151M mutations in HIV-2 infected patients receiving nucleoside reverse transcriptase inhibitors containing regimen.
|
J Med Virol
|
2004
|
1.14
|
|
12
|
Prolonged Plasmodium falciparum infection in immigrants, Paris.
|
Emerg Infect Dis
|
2008
|
1.10
|
|
13
|
Improved sensitivity of human immunodeficiency virus type 2 subtype B plasma viral load assay.
|
J Clin Microbiol
|
2005
|
1.10
|
|
14
|
Selection of the Q148R integrase inhibitor resistance mutation in a failing raltegravir containing regimen.
|
AIDS
|
2008
|
1.08
|
|
15
|
Leishmania resistance to miltefosine associated with genetic marker.
|
Emerg Infect Dis
|
2012
|
1.07
|
|
16
|
Comparison of viro-immunological marker changes between HIV-1 and HIV-2-infected patients in France.
|
AIDS
|
2008
|
1.07
|
|
17
|
Letter. In vitro phenotypic susceptibility to nucleoside reverse transcriptase inhibitors of HIV-2 isolates with the Q151M mutation in the reverse transcriptase gene.
|
Antivir Ther
|
2005
|
1.01
|
|
18
|
Impact of HIV infection on severity of imported malaria is restricted to patients with CD4 cell counts < 350 cells/microl.
|
AIDS
|
2009
|
0.99
|
|
19
|
Immunovirological response to triple nucleotide reverse-transcriptase inhibitors and ritonavir-boosted protease inhibitors in treatment-naive HIV-2-infected patients: The ACHIEV2E Collaboration Study Group.
|
Clin Infect Dis
|
2011
|
0.97
|
|
20
|
Virological and immunological response to HAART regimen containing integrase inhibitors in HIV-2-infected patients.
|
AIDS
|
2008
|
0.96
|
|
21
|
Cohort Profile: French hospital database on HIV (FHDH-ANRS CO4).
|
Int J Epidemiol
|
2014
|
0.96
|
|
22
|
Impact of stavudine phenotype and thymidine analogues mutations on viral response to stavudine plus lamivudine in ALTIS 2 ANRS trial.
|
Antivir Ther
|
2002
|
0.95
|
|
23
|
Quality control assessment of human immunodeficiency virus type 2 (HIV-2) viral load quantification assays: results from an international collaboration on HIV-2 infection in 2006.
|
J Clin Microbiol
|
2008
|
0.94
|
|
24
|
In-vitro phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitor S/GSK1349572.
|
AIDS
|
2010
|
0.93
|
|
25
|
Longitudinal study assessing the return of chloroquine susceptibility of Plasmodium falciparum in isolates from travellers returning from West and Central Africa, 2000-2011.
|
Malar J
|
2013
|
0.93
|
|
26
|
An international collaboration to standardize HIV-2 viral load assays: results from the 2009 ACHI(E)V(2E) quality control study.
|
J Clin Microbiol
|
2011
|
0.93
|
|
27
|
Hot spots of integrase genotypic changes leading to HIV-2 resistance to raltegravir.
|
Antimicrob Agents Chemother
|
2010
|
0.89
|
|
28
|
Good response to lopinavir/ritonavir-containing antiretroviral regimens in antiretroviral-naive HIV-2-infected patients.
|
AIDS
|
2009
|
0.89
|
|
29
|
Imported amoebic liver abscess in France.
|
PLoS Negl Trop Dis
|
2013
|
0.88
|
|
30
|
Performance of rapid diagnostic tests for imported malaria in clinical practice: results of a national multicenter study.
|
PLoS One
|
2013
|
0.88
|
|
31
|
Selection of K65R mutation in HIV-2-infected patients receiving tenofovir-containing regimen.
|
Antivir Ther
|
2004
|
0.87
|
|
32
|
Risk of Kaposi sarcoma during the first months on combination antiretroviral therapy.
|
AIDS
|
2013
|
0.86
|
|
33
|
A safety study of oral valganciclovir maintenance treatment of cytomegalovirus retinitis.
|
J Acquir Immune Defic Syndr
|
2002
|
0.86
|
|
34
|
Proliferative, IFNgamma and IL-2-producing T-cell responses to HIV-2 in untreated HIV-2 infection.
|
AIDS
|
2006
|
0.86
|
|
35
|
Modeling the time course of CD4 T-lymphocyte counts according to the level of virologic rebound in HIV-1-infected patients on highly active antiretroviral therapy.
|
J Acquir Immune Defic Syndr
|
2003
|
0.86
|
|
36
|
Delayed-onset hemolytic anemia in patients with travel-associated severe malaria treated with artesunate, France, 2011-2013.
|
Emerg Infect Dis
|
2015
|
0.86
|
|
37
|
Safety of protease inhibitors in HIV-infected pregnant women.
|
HIV AIDS (Auckl)
|
2013
|
0.85
|
|
38
|
Short article: Hepatitis B virus status in children born to HIV/HBV coinfected women in a French hospital: a cross-sectional study.
|
Eur J Gastroenterol Hepatol
|
2016
|
0.85
|
|
39
|
Molecular determinants of HIV-2 R5-X4 tropism in the V3 loop: development of a new genotypic tool.
|
J Infect Dis
|
2011
|
0.85
|
|
40
|
Immunovirological and therapeutic follow-up of HIV-1/HIV-2-dually seropositive patients.
|
AIDS
|
2009
|
0.85
|
|
41
|
Association of soluble CD14 and inflammatory biomarkers with HIV-2 disease progression.
|
Clin Infect Dis
|
2012
|
0.85
|
|
42
|
Long-term outcome of primary non-responders to tenofovir therapy in HIV/HBV-co-infected patients: impact of HBV genotype G.
|
Liver Int
|
2011
|
0.84
|
|
43
|
In vitro phenotypic susceptibility of HIV-2 clinical isolates to CCR5 inhibitors.
|
Antimicrob Agents Chemother
|
2011
|
0.84
|
|
44
|
Clinical and immunologic outcome in patients with human immunodeficiency virus infection, according to virologic efficacy in the year after virus undetectability, during antiretroviral therapy.
|
Clin Infect Dis
|
2003
|
0.82
|
|
45
|
Long-term nonprogressors and elite controllers in the ANRS CO5 HIV-2 cohort.
|
AIDS
|
2011
|
0.81
|
|
46
|
Atovaquone-proguanil in the treatment of imported uncomplicated Plasmodium falciparum malaria: a prospective observational study of 553 cases.
|
Malar J
|
2013
|
0.81
|
|
47
|
Concordance between HIV-2 genotypic coreceptor tropism predictions based on plasma RNA and proviral DNA.
|
AIDS
|
2013
|
0.80
|
|
48
|
Impact of gag genetic determinants on virological outcome to boosted lopinavir-containing regimen in HIV-2-infected patients.
|
AIDS
|
2013
|
0.80
|
|
49
|
Recombination of hepatitis B virus DNA in patients with HIV.
|
Gut
|
2011
|
0.78
|
|
50
|
Long-lasting persistence of integrase resistance mutations in HIV-2-infected patients after raltegravir withdrawal.
|
Antivir Ther
|
2011
|
0.78
|
|
51
|
Quasispecies analysis and in vitro susceptibility of HBV strains isolated from HIV-HBV-coinfected patients with delayed response to tenofovir.
|
Antivir Ther
|
2012
|
0.77
|
|
52
|
Quantitation of cytomegalovirus (CMV) DNA by real-time PCR for occurrence of CMV disease in HIV-infected patients receiving highly active antiretroviral therapy.
|
J Med Virol
|
2003
|
0.77
|
|
53
|
Pharmacokinetics, safety and efficacy of ritonavir-boosted atazanavir (300/100 mg once daily) in HIV-1-infected pregnant women.
|
Antivir Ther
|
2015
|
0.75
|
|
54
|
Significant differences in DNA viral load between HIV-1 and HIV-2 infected patients.
|
AIDS
|
2008
|
0.75
|
|
55
|
Tropism distribution among antiretroviral-naive HIV-2-infected patients.
|
AIDS
|
2015
|
0.75
|
|
56
|
Effectiveness and cost of quick diagnostic tests to determine tetanus immunity in patients with a wound in French emergency departments.
|
BMC Infect Dis
|
2014
|
0.75
|
|
57
|
Influence of geographic origin, sex, and HIV transmission group on the outcome of first-line combined antiretroviral therapy in France.
|
AIDS
|
2016
|
0.75
|
|
58
|
No association between GB virus C infection and disease progression in HIV-2-infected patients from the French ANRS HIV-2 cohort.
|
AIDS
|
2006
|
0.75
|
|
59
|
HIV-2 Vif Diversity Among Defective and Nondefective Sequences.
|
J Acquir Immune Defic Syndr
|
2016
|
0.75
|
|
60
|
Transmitted drug resistance in French HIV-2-infected patients.
|
AIDS
|
2013
|
0.75
|
|
61
|
Quantitative markers for cytomegalovirus disease in HIV-infected patients receiving highly active antiretroviral therapy.
|
AIDS
|
2003
|
0.75
|
|
62
|
High level of APOBEC3F/3G editing in HIV-2 DNA vif and pol sequences from antiretroviral-naive patients.
|
AIDS
|
2015
|
0.75
|
|
63
|
HIV-2 X4 tropism is associated with lower CD4+ cell count in treatment-experienced patients.
|
AIDS
|
2014
|
0.75
|
|
64
|
[Which future for HIV-infected children at adolescence and adulthood? ].
|
Rev Prat
|
2014
|
0.75
|
|
65
|
[Histoplasmosis leading to diagnosis of HIV infection].
|
Presse Med
|
2006
|
0.75
|
|
66
|
Dual nucleoside reverse transcriptase inhibitor therapy in the combination antiretroviral therapy era and predictors of discontinuation or switch to combination antiretroviral therapy.
|
J Acquir Immune Defic Syndr
|
2008
|
0.75
|